Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015


News provided by

Research and Markets

31 Aug, 2015, 05:10 GMT

Share this article

Share toX

Share this article

Share toX

DUBLIN, Aug. 28, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/g4msr8/cancer_cd) has announced the addition of the "Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015" report to their offering.

Continue Reading
This image opens in the lightbox
Research and Markets Logo. (PRNewsFoto/PR NEWSWIRE EUROPE)

Pharmaceutical companies are continuously looking for better therapeutic options to effectively cure and prevent various malignancies. Several options for cancer treatment are available belonging to various classes of molecules. Different types of cancer have different pathophysiological characteristics due to which distinctive approach is required for effective treatment. Several molecules have been discovered out of which CD antigens have been found to play an important role in cancer progression and proliferation. Investigators are trying to assign different functions to CD antigens by doing extensive research and development. Their role in cancer development has been noted due to which lots of progress would be observed in this segment. Most of the work has been done in cancer segment and pharmacological profiles are expected to be improved in coming years.

CD antigen cancer therapeutics have diverse design and target due to which they could be used for several malignancies. Presence of BiTEs, ADC, monoclonal antibodies and tri-functional antibodies for targeting different CD antigens has been commercialized. Next step is assumed to be the improvement in design as complexity at molecular levels makes it difficult to manufacture them in large quantities. This issue not only decreases the productivity but also increases the cost of production. Higher cost of end products limits the number of cancer patients choosing them as a part of their regular therapeutic regime. With the use of advanced technology it is expected that this issue would be overcome in coming years. Some of the progress could be observed in case of monoclonal antibodies and same scenario could be observed for other CD antigen cancer therapeutics in coming years.

Clinical trials are being instigated across the globe in order to extend their utilities in different malignancies. They are versatile in nature due to which they could be used as a part of combinatorial therapy along with monoclonal antibodies. Their utilities in different malignancies are also being studied but results of such clinical trials remains elusive. They have strong clinical pipeline due to which several products would be introduced in coming years. However, these products are at different stages of clinical pipeline and they may take long winding times as lots of experiments proving their safety and efficacy has to be done. With time more CD antigens are expected to be discovered and they would help in the increased market size. Commercial success of marketed CD antigen cancer therapeutics shows that they would be generating significant revenues in coming years.

CD antigen cancer market is expected to witness introduction of several products which will help the pharmaceutical companies to generate significant revenues. Increasing demand for better therapeutics, large unmet medical necessities and large numbers of cancer patient's patient are expected to be responsible for the growth of this market segment. Increased funding in research and development along with utilization of advanced technology will also help in increasing their market shares across the globe. Numerous innovative CD antigen cancer therapeutics are at different stages of clinical trials which would increase their market shares. Despite these facts they have higher prices and their manufacturing is difficult but utilization of advanced technology along with streamlining of various processes are expected to overcome this barrier. In this way, future of CD antigen cancer therapeutics looks optimistic due to their superior pharmacological profiles.

CD Antigens Segments in Report:

CD3, CD4, CD9, CD11, CD19, CD20, CD22, CD26, CD27, CD28, CD29, CD33, CD37, CD40, CD44, CD45, CD47, CD52¸ CD55, CD56, CD66, CD70, CD74, CD80, CD95, CD98, CD100, CD117, CD135, CD137, CD152, CD200, CD223, CD227, CD246, CD248, CD274, CD276, CD279

Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015 Report Highlight:

- Nomenclature & Classification of CD Antigens - Mechanism of CD Antigen Cancer Therapeutics - Cancer CD Antigen Therapy Market Overview - Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase - Cancer CD Antigen Inhibitors Clinical Pipeline: 207 Drugs - Marketed Cancer CD Antigen Inhibitors: 27 Drugs - Majority of Cancer CD Antigen Inhibitors in Preclinical Phase: 70 Drugs - Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 44 Drugs - Cancer CD Antigens Clinical Pipeline is Represented in 52 Graphs & Charts

Companies Mentioned

- ARIAD Pharmaceuticals - AXXO - Alexion Pharmaceuticals - AryoGen Biopharma - Bayer HealthCare - Biocad - Biogen - Biotecnol Inc. - Bristol-Myers Squibb - Chugai Pharmaceutical - Dr Reddy's Laboratories - Eisai Co Ltd - Emergent BioSolutions - Genmab - ImmunoGen - Intas Biopharmaceuticals - MacroGenics - MedImmune - Merck - Novartis - Ono Pharmaceutical - Onyx Pharmaceuticals - PROBIOMED - Pfizer - Roche - UCB - Xencor

For more information visit http://www.researchandmarkets.com/research/g4msr8/cancer_cd

Media Contact:

Laura Wood, +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.